Skip to main content

Table 2 Baseline patient characteristics (n = 62)

From: Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis

Variables

n (%)

Mean (SD)

Female / Male

55 (88.7) / 7 (11.3)

 

Age at diagnosis, years

 

48.1 (14.9)

Disease duration, years

 

17.1 (10.9)

Erosive RA

36 (58.1)

 

RF positive

46 (74.2)

 

ACPA positive

42 (67.8)

 

Smoking habit

 Non-smoker

36 (58.1)

 

 Ex-smoker

11 (17.7)

 

 Smoker

6 (9.7)

 

Missing data

9 (14.5)

 

Body mass index

 

28.8 (6.3)

Number of previous cDMARDs

 

2.5 (1.3)

Number of previous bDMARDs

 

2.8 (2.2)

Duration of treatment, months

 

18.2 (14.4)

Baseline DAS28

 

5.3 (1.2)

Baseline CDAI

 

24.9 (9.8)

  1. Abbreviations: RA Rheumatoid arthritis, ACPA Anticitrullinated protein antibodies, DAS28 Disease Activity Score including 28 joints, bDMARD biological disease-modifying antirheumatic drug, cDMARD conventional biological disease-modifying antirheumatic drug, CDAI Clinical Disease Activity Index, RF Rheumatoid factor